Salve Therapeutics


Over 5% of newborns suffer from a genetic disease. These include single gene, polygenic and chromosomal disorders. Many other non-congenital diseases with genetic components are activated by environmental triggers (autoimmune, cancer, tissue injury). Sophisticated gene therapies could cure these diseases and significantly ease patient burden and improve quality of life. Current gene therapies are mostly limited to plasmid-based and Adeno-associated virus variants with inefficient response rates and limited use. Better viral delivery methods would expand the available pharmacopeia to produce precision medicines for intractable and incurable genetic diseases.

Salve Therapeutics of Los Angeles, CA, USA is building VirCAD© (Virus Computer-Aided Design), an HPC-powered, AI/ML/Edge-capable bioCAD platform to mine, design, model and test new viral drugs for improved cell and gene therapies, vaccines, oncolytics, antibiotics and other categories. These modalities will treat the many inherited and acquired genetic disorders afflicting patients due to their therapeutic specificity, efficiency, and customizability.